ZENERLY Trademark

Trademark Overview

On Thursday, May 11, 2017, a trademark application was filed for ZENERLY with the United States Patent and Trademark Office. The USPTO has given the ZENERLY trademark a serial number of 87445606. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 8, 2020. This trademark is owned by Sage Therapeutics, Inc.. The ZENERLY trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations for treating diseases and disorders of the central nervous system, epilepsy, and depression
zenerly

General Information

Serial Number87445606
Word MarkZENERLY
Filing DateThursday, May 11, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 8, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 29, 2017

Trademark Statements

Goods and Servicespharmaceutical preparations for treating diseases and disorders of the central nervous system, epilepsy, and depression

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, May 16, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSage Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142
Party NameSage Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Trademark Events

Event DateEvent Description
Monday, June 8, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, June 8, 2020ABANDONMENT - NO USE STATEMENT FILED
Monday, February 10, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Saturday, October 5, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 3, 2019EXTENSION 4 GRANTED
Thursday, October 3, 2019EXTENSION 4 FILED
Thursday, October 3, 2019TEAS EXTENSION RECEIVED
Wednesday, April 24, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 22, 2019EXTENSION 3 GRANTED
Monday, April 22, 2019EXTENSION 3 FILED
Monday, April 22, 2019TEAS EXTENSION RECEIVED
Monday, April 8, 2019ASSIGNED TO EXAMINER
Friday, October 19, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 17, 2018EXTENSION 2 GRANTED
Wednesday, October 17, 2018EXTENSION 2 FILED
Wednesday, October 17, 2018TEAS EXTENSION RECEIVED
Friday, April 20, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 18, 2018EXTENSION 1 GRANTED
Wednesday, April 18, 2018EXTENSION 1 FILED
Wednesday, April 18, 2018TEAS EXTENSION RECEIVED
Tuesday, October 24, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 29, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 29, 2017PUBLISHED FOR OPPOSITION
Wednesday, August 9, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 25, 2017ASSIGNED TO LIE
Monday, July 3, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, June 13, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, June 12, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, June 12, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, June 6, 2017NOTIFICATION OF PRIORITY ACTION E-MAILED
Tuesday, June 6, 2017PRIORITY ACTION E-MAILED
Tuesday, June 6, 2017PRIORITY ACTION WRITTEN
Monday, June 5, 2017ASSIGNED TO EXAMINER
Tuesday, May 16, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, May 15, 2017NEW APPLICATION ENTERED IN TRAM

Related Keywords

zenerly nervous system epilepsy depression central disorders preparations treating diseases pharmaceutical